中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (01): 6-9.doi: 10.3969/j.issn.1671-4091.2022.01.002

• 专题讲座 • 上一篇    下一篇

肾性贫血的治疗研究

傅晓岑1,任红1,陈楠1   

  1. 1上海交通大学医学院附属瑞金医院肾脏内科
  • 收稿日期:2021-10-09 修回日期:2021-10-20 出版日期:2022-01-12 发布日期:2022-01-04
  • 通讯作者: 陈楠 cnrj100@126.com E-mail:cnrj100@126.com

Treatment of renal anemia

  1. 1Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China
  • Received:2021-10-09 Revised:2021-10-20 Online:2022-01-12 Published:2022-01-04

PDF

772

摘要： 【摘要】贫血是慢性肾脏病患者常见并发症，与患者肾脏疾病进展、远期生存、心血管不良事件等均有关。目前有许多新药可应用于临床治疗，包括低氧诱导因子脯氨酰羟化酶抑制剂、新型静脉铁剂、长效红细胞生成素等，可有效纠正贫血。本文综述了肾性贫血的治疗进展，为肾性贫血管理提供循证依据。

关键词: 慢性肾脏病, 贫血, 红细胞生成刺激剂, 低氧诱导因子脯氨酰羟化酶抑制剂

Abstract: 【Abstract】Anemia is a common complication and is related to progression of the kidney disease, longterm survival and adverse cardiovascular events in chronic kidney disease patients. Many new drugs can be clinically used to treat the anemia, including hypoxia-inducible factor prolyl hydroxylase inhibitors, new intravenous iron reagents, long-acting erythropoietin, etc. This article summarizes the progresses in the treatment of renal anemia so as to provide the evidence-based methods for clinical management of renal anemia.


Key words: Chronic kidney disease, Anemia, Erythropoiesis-stimulating agent, Hypoxia-inducible factor prolyl hydroxylase inhibitor

中图分类号: